Semax
FDA says human safety information is absent or limited for proposed routes.
Keep the safety limits visible.
FDA identifies possible immunogenicity risks with compounded semax from aggregation and peptide-related impurities. The entry concerns certain routes of administration, not a complete evaluation of every product bearing this name.
FDA says it has no, or limited, safety-related information for proposed routes and cannot sufficiently determine whether the drug would cause harm in humans. Absence of safety data is not proof of safety.
This source does not establish a cognitive-enhancement benefit or support a treatment recommendation. No dosing, injection instructions or purchase links are provided.
Interpretation is limited to the source linked above. Independent medical review pending.